Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Here is the second part of the presentation on "Lung Cancer Highlights, 2011" by Dr. Jared Weiss. This section of his talk focuses on the striking story of the identification of the ALK rearrangement as a relevant target in lung cancer, along with an impressive treatment for this subgroup, and other new targets, such as ROS-1.
Below you'll find the audio and video versions of the podcast, as well as the transcript and figures.
Dr. Weiss Lung Cancer Highlights 2011, Pt 2 ALK and New Molecular Targets Audio Podcast
Dr. Weiss Lung Cancer Highlights 2011, Pt 2 ALK and New Molecular Targets Transcript
Dr. Weiss Lung Cancer Highlights 2011 Pt 2 ALK and New Molecular Targets Figs
The third and final part of Dr. Weiss's presentation will focus on advances for broader populations: smokers and the elderly. He'll cover the lung cancer screening trial known as the NLST, as well as an influential presentation of single agent vs. doublet chemotherapy in elderly patients with advanced NSCLC. Look for that here very soon.
Thanks again to LUNGevity Foundation for their sponsorship of this work with us, making this content possible.
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: